ENGN
enGene Therapeutics Inc.Company with tickers: ENGN, ENGNW
CIK
1980845
CUSIP
29286M105
Shares Outstanding
66,989,466
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $31,185,000 | USD | 2026-01-31 | 10-Q | 2026-03-09 |
| Research & Development | $22,255,000 | USD | 2026-01-31 | 10-Q | 2026-03-09 |
| Operating Income | $-31,185,000 | USD | 2026-01-31 | 10-Q | 2026-03-09 |
| Net Income | $-29,752,000 | USD | 2026-01-31 | 10-Q | 2026-03-09 |
| EPS (Basic) | $0.44 | USD/shares | 2026-01-31 | 10-Q | 2026-03-09 |
| EPS (Diluted) | $0.44 | USD/shares | 2026-01-31 | 10-Q | 2026-03-09 |